Followers | 4054 |
Posts | 151840 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
![](https://investorshub.advfn.com/uicon/162645.png?cb=1681428050)
Friday, June 05, 2020 8:13:17 AM
On June 4, 2020, Tetraphase Pharmaceuticals, Inc. (the “Company”) received notice that the United States Food and Drug Administration (the “FDA”) approved the Company’s supplemental New Drug application (“sNDA”) for a new strength of XERAVATM (eravacycline) for injection for the treatment of complicated intra-abdominal infections in adult patients containing 100mg of eravacycline per vial as well as an extension of the “in-use” shelf life for XERAVA diluted ready for infusion IV solution from 7 days to 10 days under refrigerated conditions for the existing 50 mg/vial product and for the newly approved 100 mg/vial product.
https://ih.advfn.com/stock-market/NASDAQ/tetraphase-pharmaceuticals-TTPH/stock-news/82607977/current-report-filing-8-k
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
https://ih.advfn.com/stock-market/NASDAQ/tetraphase-pharmaceuticals-TTPH/stock-news/82601296/melinta-therapeutics-to-acquire-tetraphase-pharmac
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM